Peginterferon alfa-2a (Pegasys)

Current understanding

Pegylated interferon alfa-2a is used off-label in MPN (PV, ET, MF) and achieves hematological and molecular responses, with the most consistent allele-burden reductions in JAK2V617F-mutant disease. CALR-mutant patients show heterogeneous and generally lower molecular responses, and the precise mechanisms by which IFNα targets malignant hematopoietic stem cells — including predictors of deep molecular response (DMR) — remain incompletely defined (review-level synthesis).

Evidence log

Open questions

Related